FIRE AB

[anonymous]

Used to work there. Am retired now. I understand some of the structural problems from the past. I understand under performing research division. Nothing new there. What else?

Sr. level exec institutional rot, people who believe they are so important they write books that no one but other Pfizer execs read...then they promote each others books on LinkedIn...they are also more interested in focusing on social initiatives than company performance. Getting rid of AB, Sally Sussman, most of R&D leadership and a few other sr. execs would be a good start...

 

[anonymous]

Sr. level exec institutional rot, people who believe they are so important they write books that no one but other Pfizer execs read...then they promote each others books on LinkedIn...they are also more interested in focusing on social initiatives than company performance. Getting rid of AB, Sally Sussman, most of R&D leadership and a few other sr. execs would be a good start...

Geez, you complain about the same two things ad nauseam on this site, regardless of thread topic. There are plenty of things wrong with this company. It has been this way since the 90s. If their book-writing so offers you, dont read the books. Or author your own, rebutting everything they say in their books. If their social justice warrior-ship concerns you so much, craft them an email and send it to them. Or resign.
We have far bigger problems here than the two you state over and over and over. If you've worked here as long as I, you would know that. Our problems existed for decades, well before AB and Sally so offended you.
If you dont believe me, check out our stock value from 2002 to now. How many CEOs have we had? How many General Biz Managers or Sales VPs have been escorted out the front door by security?

 

[anonymous]

Geez, you complain about the same two things ad nauseam on this site, regardless of thread topic. There are plenty of things wrong with this company. It has been this way since the 90s. If their book-writing so offers you, dont read the books. Or author your own, rebutting everything they say in their books. If their social justice warrior-ship concerns you so much, craft them an email and send it to them. Or resign.
We have far bigger problems here than the two you state over and over and over. If you've worked here as long as I, you would know that. Our problems existed for decades, well before AB and Sally so offended you.
If you dont believe me, check out our stock value from 2002 to now. How many CEOs have we had? How many General Biz Managers or Sales VPs have been escorted out the front door by security?

Remember Sales VP Mick Mosebrook? At national sales meetings, he would sit in his limo outside of the auditorium until time for his brief presentation, then go in and speak to the sales force for about 30 minutes and return to his limo - so that he did not have to interact with the lowly employees! Sally Sussman has her position because of her father. All of these people were/ are losers and it is time to dismantle Pfizer.

 

[anonymous]

Remember Sales VP Mick Mosebrook? At national sales meetings, he would sit in his limo outside of the auditorium until time for his brief presentation, then go in and speak to the sales force for about 30 minutes and return to his limo - so that he did not have to interact with the lowly employees! Sally Sussman has her position because of her father. All of these people were/ are losers and it is time to dismantle Pfizer.

Since I came here in the late 90s, Pfizer leadership has been known for cronyism and nepotism being two of THE most important factors in selecting district and regional managers and above. I did an internship in marketing in early 2000s and heard the loud complaints from the former Pharmacia marketers that were brave enough to make the switch after the acquisition.

 

[anonymous]

AB quotes Reuters this morning
“Pfizer's launch of its respiratory syncytial virus (RSV) vaccine Abrysvo last year has also been a disappointment, Bourla said, only taking roughly 35% of market share in the United States, badly lagging a rival vaccine from GSK (GSK.L).


"For me that was very unacceptable and doesn't reflect anything other than GSK were able to do better contracting and better commercial execution," Bourla said.

He said most of the RSV vaccines were administered in pharmacies, where GSK was able to dominate. For much of the season, GSK's was the only shot offered by CVS Health (CVS.N), the biggest U.S. pharmacy chain in the U.S. and a dominant player in the retail vaccine market.

Bourla said the company was not happy with the performance of its commercial operation in 2023. Former Chief Commercial Officer Angela Hwang stepped down last month, and the company split its commercial business into two divisions, one focused on the United States and the other on the rest of the world.

"Overall, Pfizer didn't demonstrate that edge that we had as a commercial machine that used to be a well oiled machine that was very credible launching products and we took some measures to correct that," Bourla said.”

Ah, thanks AB, now we understand. It was Angela’s fault. It’s the commercial organization’s fault. Don’t you realize how vaccine contracting works and the need to have a range of products to bundle? That you must be willing to include significant concessions on your lead product (PVC20) to get traction for RSV or MnB? Whomever accepted or drove the covid forecast should be fired for incompetence. If you drove that disconnected from reality “bold thinking”, you should be the first one walked out.

In other comments he said PFE is committed to “play” in the weight loss market. Another place where PFE will be late to the market, with an equal to or lesser product, in a category that is losing steam due to rebound from over zealous use.

Koalemos. Get rid of this chucklehead before he completely demolishes this company that he realizes was once proud, productive and focused on healthcare business.

 

[anonymous]

Good points. Will be important to watch how the market responds to the JP Morgan healthcare Conference this week. If PFE doesn’t show well relative to others presenting or get some love from the market, it should tell the board that AB is done. PFE needs bounce and this is the showcase to do it.

 

[anonymous]

Good points. Will be important to watch how the market responds to the JP Morgan healthcare Conference this week. If PFE doesn’t show well relative to others presenting or get some love from the market, it should tell the board that AB is done. PFE needs bounce and this is the showcase to do it.

 

[anonymous]

AB quotes Reuters this morning
“Pfizer's launch of its respiratory syncytial virus (RSV) vaccine Abrysvo last year has also been a disappointment, Bourla said, only taking roughly 35% of market share in the United States, badly lagging a rival vaccine from GSK (GSK.L).


"For me that was very unacceptable and doesn't reflect anything other than GSK were able to do better contracting and better commercial execution," Bourla said.

He said most of the RSV vaccines were administered in pharmacies, where GSK was able to dominate. For much of the season, GSK's was the only shot offered by CVS Health (CVS.N), the biggest U.S. pharmacy chain in the U.S. and a dominant player in the retail vaccine market.

Bourla said the company was not happy with the performance of its commercial operation in 2023. Former Chief Commercial Officer Angela Hwang stepped down last month, and the company split its commercial business into two divisions, one focused on the United States and the other on the rest of the world.

"Overall, Pfizer didn't demonstrate that edge that we had as a commercial machine that used to be a well oiled machine that was very credible launching products and we took some measures to correct that," Bourla said.”

Ah, thanks AB, now we understand. It was Angela’s fault. It’s the commercial organization’s fault. Don’t you realize how vaccine contracting works and the need to have a range of products to bundle? That you must be willing to include significant concessions on your lead product (PVC20) to get traction for RSV or MnB? Whomever accepted or drove the covid forecast should be fired for incompetence. If you drove that disconnected from reality “bold thinking”, you should be the first one walked out.

In other comments he said PFE is committed to “play” in the weight loss market. Another place where PFE will be late to the market, with an equal to or lesser product, in a category that is losing steam due to rebound from over zealous use.

Koalemos. Get rid of this chucklehead before he completely demolishes this company that he realizes was once proud, productive and focused on healthcare business.

Guess what Albert? We are not happy with YOUR performance! This guy is unbelievable

 

[anonymous]

Remember Sales VP Mick Mosebrook? At national sales meetings, he would sit in his limo outside of the auditorium until time for his brief presentation, then go in and speak to the sales force for about 30 minutes and return to his limo - so that he did not have to interact with the lowly employees! Sally Sussman has her position because of her father. All of these people were/ are losers and it is time to dismantle Pfizer.

see that’s not really fair, Sally Sussman just wrote a book!

 

[anonymous]

We don’t bundle. Our competitors do. We will always be disadvantaged.

 

[anonymous]

We don’t bundle. Our competitors do. We will always be disadvantaged.

Think anyone has explained that to AB? If yes, we can assume he ignored it.

 

[anonymous]

Guess what Albert? We are not happy with YOUR performance! This guy is unbelievable

Even a veterinarian should understand this
According to the FDA, the Arexvy vaccine reduces the risk of developing RSV-associated LRTD (lower respiratory tract disease) by 82.6% and the risk of developing severe RSV-associated LRTD by 94.1%. The ABRYSVO vaccine reduces the risk of LRTD by 65.1% and severe LRTD by 88.9%.

 

[anonymous]

AB quotes Reuters this morning
“Pfizer's launch of its respiratory syncytial virus (RSV) vaccine Abrysvo last year has also been a disappointment, Bourla said, only taking roughly 35% of market share in the United States, badly lagging a rival vaccine from GSK (GSK.L).


"For me that was very unacceptable and doesn't reflect anything other than GSK were able to do better contracting and better commercial execution," Bourla said.

He said most of the RSV vaccines were administered in pharmacies, where GSK was able to dominate. For much of the season, GSK's was the only shot offered by CVS Health (CVS.N), the biggest U.S. pharmacy chain in the U.S. and a dominant player in the retail vaccine market.

Bourla said the company was not happy with the performance of its commercial operation in 2023. Former Chief Commercial Officer Angela Hwang stepped down last month, and the company split its commercial business into two divisions, one focused on the United States and the other on the rest of the world.

"Overall, Pfizer didn't demonstrate that edge that we had as a commercial machine that used to be a well oiled machine that was very credible launching products and we took some measures to correct that," Bourla said.”

Ah, thanks AB, now we understand. It was Angela’s fault. It’s the commercial organization’s fault. Don’t you realize how vaccine contracting works and the need to have a range of products to bundle? That you must be willing to include significant concessions on your lead product (PVC20) to get traction for RSV or MnB? Whomever accepted or drove the covid forecast should be fired for incompetence. If you drove that disconnected from reality “bold thinking”, you should be the first one walked out.

In other comments he said PFE is committed to “play” in the weight loss market. Another place where PFE will be late to the market, with an equal to or lesser product, in a category that is losing steam due to rebound from over zealous use.

Koalemos. Get rid of this chucklehead before he completely demolishes this company that he realizes was once proud, productive and focused on healthcare business.

Pfizer status quo: lack of accountability when screwing up a product launch. I'm not in that division, but I've seen this act before. The whole schebang probably needs a reboot, from the marketers to whomever they use as an agency to the sales leaders.

 

[anonymous]

Good points. Will be important to watch how the market responds to the JP Morgan healthcare Conference this week. If PFE doesn’t show well relative to others presenting or get some love from the market, it should tell the board that AB is done. PFE needs bounce and this is the showcase to do it.

We have the early answer. PFE down about 1.4% today. Go to Seeking Alpha and read the transcript of the interview with Chris Schott at JP Morgan Healthcare conference. To me it reads like a second level line leader, not a senior executive. He talks about covid uncertainty, returns and write offs without explaining why(other than the stuck in moonshot mindset “we had built stocks to save the world”). He talks about approvals but never explains why those are not translating to value. He talks about blending leadership from Pfizer and Seagen without explaining the strategy and expected value from these decisions. He talks about what Pfizer used to be, as if the market owes the ghost of PFE some respect in 2024.

He is clearly far out of his depth. The street knows it but somehow the BOD doesn’t. Fools, all.

 

[anonymous]

AB quotes Reuters this morning
“Pfizer's launch of its respiratory syncytial virus (RSV) vaccine Abrysvo last year has also been a disappointment, Bourla said, only taking roughly 35% of market share in the United States, badly lagging a rival vaccine from GSK (GSK.L).


"For me that was very unacceptable and doesn't reflect anything other than GSK were able to do better contracting and better commercial execution," Bourla said.

He said most of the RSV vaccines were administered in pharmacies, where GSK was able to dominate. For much of the season, GSK's was the only shot offered by CVS Health (CVS.N), the biggest U.S. pharmacy chain in the U.S. and a dominant player in the retail vaccine market.

Bourla said the company was not happy with the performance of its commercial operation in 2023. Former Chief Commercial Officer Angela Hwang stepped down last month, and the company split its commercial business into two divisions, one focused on the United States and the other on the rest of the world.

"Overall, Pfizer didn't demonstrate that edge that we had as a commercial machine that used to be a well oiled machine that was very credible launching products and we took some measures to correct that," Bourla said.”

Ah, thanks AB, now we understand. It was Angela’s fault. It’s the commercial organization’s fault. Don’t you realize how vaccine contracting works and the need to have a range of products to bundle? That you must be willing to include significant concessions on your lead product (PVC20) to get traction for RSV or MnB? Whomever accepted or drove the covid forecast should be fired for incompetence. If you drove that disconnected from reality “bold thinking”, you should be the first one walked out.

In other comments he said PFE is committed to “play” in the weight loss market. Another place where PFE will be late to the market, with an equal to or lesser product, in a category that is losing steam due to rebound from over zealous use.

Koalemos. Get rid of this chucklehead before he completely demolishes this company that he realizes was once proud, productive and focused on healthcare business.

 

[anonymous]

Looks like AB is placing all blame at Angela's door for commercial execution and Abrysvo marketshare. Meanwhile you can see that he is still re-living in the glory days of "saving the world from Covid" and applying that same mindset to everything else. His logic is when you give impossible goals to people, even if we fail, we will be further along than we otherwise would be. Works for a crisis situation a couple of times but Pfizer is now under a permanent state of manufactured crises for the last 4-5 years - thanks to AB's endless demand of moonshot goals. By the time one moonshot goal fails, it is time to "reimagine" it and another round of restructuring starts. After 4 years of endless rounds of restructuring under AB, people have lost focus on what needs to be done and it is just CYA and politics as everyone tries to survive. If he can't turn things around in 6 months, he will hopefully run out of scapegoats to blame.

 

[anonymous]

Looks like AB is placing all blame at Angela's door for commercial execution and Abrysvo marketshare. Meanwhile you can see that he is still re-living in the glory days of "saving the world from Covid" and applying that same mindset to everything else. His logic is when you give impossible goals to people, even if we fail, we will be further along than we otherwise would be. Works for a crisis situation a couple of times but Pfizer is now under a permanent state of manufactured crises for the last 4-5 years - thanks to AB's endless demand of moonshot goals. By the time one moonshot goal fails, it is time to "reimagine" it and another round of restructuring starts. After 4 years of endless rounds of restructuring under AB, people have lost focus on what needs to be done and it is just CYA and politics as everyone tries to survive. If he can't turn things around in 6 months, he will hopefully run out of scapegoats to blame.

Firing Angela is basically firing your Offensive Coordinator or Defensive Coordinator after a sub-par year in football...someone else takes the blame, basically buying yourself a little more time "hoping" a miracle falls at your doorstep and you have a good year. The "crisis" and "fire alarm" mindset that now permeates the company is straight-up crazy. The endless restructuring doesn't lead to any kind of continuity and essentially wears people out.

 

[anonymous]

We have the early answer. PFE down about 1.4% today. Go to Seeking Alpha and read the transcript of the interview with Chris Schott at JP Morgan Healthcare conference. To me it reads like a second level line leader, not a senior executive. He talks about covid uncertainty, returns and write offs without explaining why(other than the stuck in moonshot mindset “we had built stocks to save the world”). He talks about approvals but never explains why those are not translating to value. He talks about blending leadership from Pfizer and Seagen without explaining the strategy and expected value from these decisions. He talks about what Pfizer used to be, as if the market owes the ghost of PFE some respect in 2024.

He is clearly far out of his depth. The street knows it but somehow the BOD doesn’t. Fools, all.

Read the Seeking Alpha transcript...unbelievable. I sure hope the BOD reads the transcript. Must be a helluva salesperson to stay in his current role.

 

[anonymous]

I thought Angela left on her own. Do you have proof she was let go?
Sad to see her leave - she was a great leader

 

[anonymous]

I thought Angela left on her own. Do you have proof she was let go?
Sad to see her leave - she was a great leader

I doubt that she was walked out. She seemed very loyal to AB and could have negotiated an exit. He has taken the gesture and flung her under the bus, it looks like. Conjecture, but that’s how it looks